Correction for Kovacs et al., “An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline”

Podobne zapisy

• An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline
  od: Kovacs, Steven J., i wsp.
  Wydane: (2020)
• Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects
  od: Sun, Haiying, i wsp.
  Wydane: (2016)
• Pharmacokinetics, Distribution, Metabolism, and Excretion of Omadacycline following a Single Intravenous or Oral Dose of (14)C-Omadacycline in Rats
  od: Lin, Wen, i wsp.
  Wydane: (2016)
• Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
  od: Rodvold, Keith A, i wsp.
  Wydane: (2019)
• In Vitro and In Vivo Assessments of Cardiovascular Effects with Omadacycline
  od: Tanaka, S. Ken, i wsp.
  Wydane: (2016)